Pulmonologists Crucial for Lung Cancer Biomarker Testing
Dr. Eric K. Singhi highlights the role of specialists in advancing precision lung cancer therapies at CHEST 2026.
Updated on Oct. 19, 2026 in Asthma
Live Poll
Do you trust that your local healthcare providers prioritize equitable access to necessary diagnostic testing?
At the CHEST 2026 conference in Phoenix, Dr. Eric K. Singhi emphasized that pulmonologists are essential in facilitating timely lung cancer biomarker testing. Their early involvement in the patient care process is vital to securing the tissue samples required for precise diagnostics.
Why it matters
Biomarker testing is the gateway for patients to access precise therapies, ensuring they receive the most effective treatments tailored to their specific genomic alterations. Identifying these patients through comprehensive testing is necessary to optimize long-term clinical outcomes.
There are at least 10 genomic alterations currently linked to FDA-approved matched targeted therapies. A 2024 global survey indicated that 43% of providers begin drug therapy before biomarker test results are finalized.
The players
Eric K. Singhi
Eric K. Singhi is a medical professional who presented research on the role of pulmonologists in lung cancer diagnostics at the CHEST 2026 conference.
The details
Pulmonologists are the primary clinicians tasked with obtaining the tissue samples necessary for comprehensive biomarker analysis. By engaging early, these specialists help overcome common barriers such as cost, limited access, lack of awareness, and the challenge of insufficient tissue volume.
Timeline
A global survey regarding provider biomarker testing timing was conducted in 2024.
The CHEST 2026 conference took place in Phoenix, Arizona, in 2026.
The Big Picture
This focus on biomarker optimization aligns with current initiatives presented at the CHEST 2026 conference. The findings serve to standardize diagnostic workflows to ensure more patients benefit from rapidly evolving genomic therapies.
Patients undergoing lung cancer evaluations can expect pulmonologists to play a more proactive role in scheduling biomarker tests early in the diagnosis phase. This streamlined approach is designed to prevent delays in accessing targeted drug treatments that may significantly improve health outcomes.
The takeaway
Early biomarker testing is the standard for matching lung cancer patients with successful treatment protocols. Patients should discuss the necessity and timing of these tests with their pulmonologist as soon as a potential diagnosis is identified.
Further reading
Learn more about the latest innovations in respiratory care on the United States Asthma section page.
Source note: This article includes information reported by Ajmc.
Live Poll
Do you trust that your local healthcare providers prioritize equitable access to necessary diagnostic testing?
